Today, pharma and medical imaging company MedTrace announced the appointment of Nicholas Borys, M.D., as Chief Medical Officer (CMO). Dr. Borys is a skilled and experienced healthcare executive with over 25 years experience in advancing portfolios of novel therapies across diverse indications in cardiovascular, cancer, and central nervous system disease. Among his accomplishments, he led drug development at IMUNON, Amersham, and Hoffmann-La Roche, and successfully led and completed four new drug applications. “Nick brings in-depth knowledge to MedTrace and will play a significant role in accelerating our Phase III Trial. I am incredibly pleased to have him join MedTrace and our executive management team”, CEO Ann Kristin Led says.
Nicholas Borys, MD, CMO at MedTrace has extensive global experience in leading clinical research and drug development programs for innovative therapies and diagnostics in cardiology, oncology, neurology, and nuclear medicine. He has spent 15 years as Executive Vice President and CMO at the Nasdaq-listed pharma company IMUNON and now joins MedTrace after having spent the last two years as a Consulting Chief Medical Officer at NB&C Consulting. At MedTrace he will be responsible for the successful completion of the company’s Phase III Clinical Trial.
“Nicholas Borys is a significant addition to our team, bringing an impressive track record and an extensive network that will help us further accelerate our trial site activation. We are pleased and proud to have him on board. With his expertise, our executive management team now has the strongest possible foundation to address the U.S. market, speed up our trial, and secure the necessary regulatory approvals ahead of a full market launch,” says CEO Ann Kristin Led.
As Chief Medical Officer at MedTrace, Nicholas Borys will lead the company’s Clinical, Regulatory, and Medical Affairs departments. Commenting on his new position, he said:
“Joining MedTrace, an advanced medical imaging company, has brought my career to a full circle where I can bring my experience in drug development, nuclear medicine and therapeutics together. MedTrace has developed a new generation of imaging technology that captures and precisely measures blood flow and perfusion anywhere in the body. This 15O-water point-of-care solution has the potential to completely transform the way medical imaging is performed today and helping direct optimal care of patients in the future. Currently, MedTrace is focused on cardiology, but the potential of this innovation extends into oncology and neurology, among other fields. I am thrilled to join the team bringing MedTrace’s advanced technology to the market.”
MedTrace’s Phase III Clinical Trial, Rapid Water Flow, is designed to evaluate the diagnostic accuracy and safety of 15O-water as a myocardial perfusion (Positron Emission Tomography) PET imaging agent. The approximately 182-patient trial is progressing according to the development plan and roughly one-fourth of patients have been enrolled across eight major university hospitals in Europe and North America. Read more about the trial here.
About MedTrace
MedTrace is a pharma and medical device company with a 15O-water point-of-care solution under development. The solution consists of patented hardware for on-demand manufacturing, dosing, and infusion of 15O-water and patented software to analyze PET images. The company has an ongoing Phase III Clinical Trial, RAPID-WATER-FLOW, that seeks to evaluate the diagnostic accuracy and safety of 15O-water as a myocardial perfusion PET imaging agent.
Forward-Looking Statement
This news release by MedTrace Pharma A/S (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. The company offers no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those outlined in the forward-looking statements.
